Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2993627 | 1.00 | CYP1A2 (0.44) | CYP1A2PTGDR2RAB9AALDH1A1TSHR | |
| SCHEMBL2993623 | 0.89 | RAB9A (0.47) | CYP1A2PTGDR2RAB9AALDH1A1TSHR | |
| SCHEMBL32662599 | 0.88 | CYP1A2 (0.46) | CYP1A2PTGDR2ALDH1A1MAPTHPGD | |
| SCHEMBL1525992 | 0.87 | RECQL (0.51) | RAB9AALDH1A1TSHRMAPTHPGD | |
| SCHEMBL28102381 | 0.86 | ALDH1A1 (0.46) | CYP1A2PTGDR2ALDH1A1MAPTHPGD | |
| SCHEMBL2995979 | 0.85 | CYP1A2 (0.44) | CYP1A2PTGDR2ALDH1A1MAPTHPGD | |
| SCHEMBL2995973 | 0.85 | CYP1A2 (0.44) | CYP1A2PTGDR2ALDH1A1MAPTHPGD | |
| SCHEMBL27573003 | 0.84 | TSHR (0.46) | CYP1A2PTGDR2ALDH1A1TSHRMAPT | |
| SCHEMBL5148727 | 0.83 | CYP1A2 (0.42) | CYP1A2PTGDR2ALDH1A1MAPTHPGD | |
| SCHEMBL5147272 | 0.82 | CYP1A2 (0.42) | CYP1A2PTGDR2ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130904-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2026-05-14 | — | — | US | disclosed |
| US-20240101584-A1 | TARGETED DELIVERY OF 1,2,4,5 TETRAOXANE COMPOUNDS AND THEIR USES | Westlake University (CN) | 2024-03-28 | — | — | US | disclosed |
| US-20230099694-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-03-30 | — | — | US | disclosed |
| US-20210052575-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-25 | — | — | US | disclosed |
| US-20200061056-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-02-27 | — | — | US | disclosed |
| US-20190167672-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-06-06 | — | — | US | disclosed |
| US-20180318294-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-11-08 | — | — | US | disclosed |
| US-20180092907-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-04-05 | — | — | US | disclosed |
| US-20170071933-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-03-16 | — | — | US | disclosed |
| EP-2753617-B9 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMA CO LTD (JP) | 2017-01-25 | — | — | EP | disclosed |
| US-20150045356-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-02-12 | — | — | US | disclosed |
| CN-103781783-A | Piperazine-substituted benzothiophene derivatives as antipsychotic agents | OTSUKA PHARMA CO LTD | 2014-05-07 | — | — | CN | disclosed |
| WO-2013035892-A1 | PIPERAZINE- SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-14 | — | — | WO | disclosed |
| US-20100184812-A1 | MUTUAL PRODRUGS AND METHODS TO TREAT CANCER | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-07-22 | — | — | US | disclosed |
| EP-2164480-A1 | MUTUAL PRODRUGS AND METHODS TO TREAT CANCER | University of Maryland, Baltimore (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008154372-A1 | MUTUAL PRODRUGS AND METHODS TO TREAT CANCER | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2008-12-18 | — | — | WO | disclosed |
| EP-0830372-B1 | CYCLIC PRODRUGS OF PEPTIDES AND PEPTIDE NUCLEIC ACIDS HAVING IMPROVED METABOLIC STABILITY AND CELL MEMBRANE PERMEABILITY | UNIV KANSAS (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-0830372-A1 | CYCLIC PRODRUGS OF PEPTIDES AND PEPTIDE NUCLEIC ACIDS HAVING IMPROVED METABOLIC STABILITY AND CELL MEMBRANE PERMEABILITY | THE UNIVERSITY OF KANSAS (US) | 1998-03-25 | — | — | EP | disclosed |
| WO-1997039024-A1 | CYCLIC PRODRUGS OF PEPTIDES AND PEPTIDE NUCLEIC ACIDS HAVING IMPROVED METABOLIC STABILITY AND CELL MEMBRANE PERMEABILITY | THE UNIVERSITY OF KANSAS (US) | 1997-10-23 | — | — | WO | disclosed |
| US-5672584-A | MODIFIED WITH END GROUPS | THE UNIVERSITY OF KANSAS (US) | 1997-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230099694-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | SUZ12, BRPF3, BRD4 | CYP1A2 211/4885PTGDR2 1135/4885RAB9A 3372/4885 |
| US-20170071933-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | SUZ12, BRPF3, BRD4 | CYP1A2 211/4885PTGDR2 1135/4885RAB9A 3372/4885 |
| US-20240101584-A1 | TARGETED DELIVERY OF 1,2,4,5 TETRAOXANE COMPOUNDS AND THEIR USES | AIFM2, GPX1, GPX4 | CYP1A2 2727/4885PTGDR2 656/4885RAB9A 1865/4885 |
| US-20180318294-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | SUZ12, BRPF3, BRD4 | CYP1A2 211/4885PTGDR2 1135/4885RAB9A 3372/4885 |
| US-20260130904-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | EBP, SIGMAR1, EP300 | CYP1A2 537/4885PTGDR2 933/4885RAB9A 3413/4885 |
| US-20210052575-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | SUZ12, SULT2A1, CYP4Z1 | CYP1A2 109/4885PTGDR2 431/4885RAB9A 3296/4885 |
| US-20200061056-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | SUZ12, BRPF3, BRD4 | CYP1A2 211/4885PTGDR2 1135/4885RAB9A 3372/4885 |
| US-20180092907-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | SUZ12, BRPF3, BRD4 | CYP1A2 211/4885PTGDR2 1135/4885RAB9A 3372/4885 |
| US-20190167672-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | SUZ12, BRPF3, BRD4 | CYP1A2 211/4885PTGDR2 1135/4885RAB9A 3372/4885 |
| US-20100184812-A1 | MUTUAL PRODRUGS AND METHODS TO TREAT CANCER | RARA, RARB, RARG | CYP1A2 390/4885PTGDR2 1328/4885RAB9A 1177/4885 |
| US-20150045356-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | SUZ12, BRPF3, BRD4 | CYP1A2 211/4885PTGDR2 1135/4885RAB9A 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.